Fluoxetine updated on 07-01-2025

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7469
R22231		 Anderson, 2020 Hypospadias, 2nd or 3rd degree 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.78 [0.44;1.38] -/-   0/- - -
ref
S6004
R15373		 Furu, 2015 Hypospadias 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.39 [0.87;2.22] 18/6,250   4,526/2,266,875 4,544 6,250
ref
S7349
R21453		 Wemakor, 2015 Hypospadias 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.42 [0.10;1.75] C 2/29   3,039/20,095 3,041 29
ref
S18282
R76939		 Reis (Controls exposed to TCA), 2010 Hypospadias early pregnancy population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.61 [0.20;1.81] C
excluded (control group) 		5/1,522   9/1,662 14 1,522
ref
S18281
R76933		 Reis (Controls unexposed, NOS), 2010 Hypospadias early pregnancy population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.10 [0.36;2.57] 5/1,522   -/1,062,190 - 1,522
ref
S6157
R16123		 Louik, 2007 Hypospadias 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.70 [0.20;2.40] 3/64   494/6,293 497 64
ref
Total 5 studies 1.00 [0.70;1.42] 8,082 7,865
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson, 2020Anderson, 2020 0.78[0.44; 1.38]--31%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Furu, 2015Furu, 2015 1.39[0.87; 2.22]4,5446,25043%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Wemakor, 2015Wemakor, 2015 0.42[0.10; 1.75]3,041296%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Reis (Controls unexposed, NOS), 2010Reis, 2010 1 1.10[0.36; 2.57]-1,52212%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: unclearROB reporting: moderate Louik, 2007Louik, 2007 0.70[0.20; 2.40]497648%ROB confusion: moderateROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Total (5 studies) I2 = 9% 1.00[0.70; 1.42]8,0827,8650.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.33[0.87; 2.03]4,5447,7720%NAFuru, 2015 Reis (Controls unexposed, NOS), 2010 2 case control studiescase control studies 0.71[0.44; 1.16]3,538930%NAAnderson, 2020 Wemakor, 2015 Louik, 2007 3 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.00[0.70; 1.42]8,0827,8659%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 5 Tags Adjustment   - No  - No 0.42[0.10; 1.75]3,04129 -NAWemakor, 2015 1   - Yes  - Yes 1.07[0.77; 1.48]5,0417,8360%NAAnderson, 2020 Furu, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 4 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 0.94[0.54; 1.66]7,5856,27950%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 3   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.92[0.43; 2.00]4971,5860%NAReis (Controls unexposed, NOS), 2010 Louik, 2007 2 All studiesAll studies 1.00[0.70; 1.42]8,0827,8659%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 50.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-1.71.70.8800.000Anderson, 2020Furu, 2015Wemakor, 2015Reis (Controls unexposed, NOS), 2010Louik, 2007

Asymetry test p-value = 0.2094 (by Egger's regression)

slope=0.5449 (0.3609); intercept=-1.5765 (0.9896); t=1.5930; p=0.2094

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 18282

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.00[0.70; 1.42]8,0827,8659%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 5 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.61[0.20; 1.81]141,522 -NAReis (Controls exposed to TCA), 2010 10.510.01.0